Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2009 (2009), Article ID 412908, 11 pages
http://dx.doi.org/10.1155/2009/412908
Review Article

Biomolecular Markers in Cancer of the Tongue

Departments of Oncology and Pathology, San Paolo Hospital, University of Milan, 20142 Milano, Italy

Received 1 March 2009; Accepted 23 June 2009

Academic Editor: Amanda Psyrri

Copyright © 2009 Daris Ferrari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. M. Pimenta Amaral, F. Da Silva, A. L. Carvalho, C. A. L. Pinto, and L. P. Kowalski, “Predictive factors of occult metastasis and prognosis of clinical stages I and II squamous cell carcinoma of the tongue and floor of the mouth,” Oral Oncology, vol. 40, no. 8, pp. 780–786, 2004. View at Publisher · View at Google Scholar · View at PubMed
  2. D. Kademani, R. B. Bell, S. Bagheri et al., “Prognostic factors in intraoral squamous cell carcinoma: the influence of histologic grade,” Journal of Oral and Maxillofacial Surgery, vol. 63, no. 11, pp. 1599–1605, 2005. View at Publisher · View at Google Scholar · View at PubMed
  3. S. P. Shantz, L. B. Harrison, and A. A. Forastiere, “Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity, and oropharynx,” in Principles and Practice of Oncology, T. De Vita, S. Hellman, and S. A. Rosemberg, Eds., 7th edition.
  4. R. M. Byers, “Squamous cell carcinoma of the oral tongue in patients less than thirty years of age,” American Journal of Surgery, vol. 130, no. 4, pp. 475–478, 1975. View at Google Scholar
  5. J. B. Jones, H. B. Lampe, and H. W. Cheung, “Carcinoma of the tongue in young patients,” Journal of Otolaryngology, vol. 18, no. 3, pp. 105–108, 1989. View at Google Scholar
  6. C. D. Llewellyn, N. W. Johnson, and K. A. Warnakulasuriya, “Risk factors for squamous cell carcinoma of the oral cavity in young people—a comprehensive literature review,” Oral Oncology, vol. 37, no. 5, pp. 401–418, 2001. View at Publisher · View at Google Scholar
  7. C. H. Shiboski, B. L. Schmidt, and R. C. K. Jordan, “Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20–44 years,” Cancer, vol. 103, no. 9, pp. 1843–1849, 2005. View at Publisher · View at Google Scholar · View at PubMed
  8. K. Annertz, H. Anderson, A. Biörklund et al., “Incidence and survival of squamous cell carcinoma of the tongue in Scandinavia, with special reference to young adults,” International Journal of Cancer, vol. 101, no. 1, pp. 95–99, 2002. View at Publisher · View at Google Scholar · View at PubMed
  9. R. H. Depue, “Rising mortality from cancer of the tongue in young white males,” The New England Journal of Medicine, vol. 315, no. 10, pp. 647–468, 1986. View at Google Scholar
  10. J. N. Sarkaria and P. M. Harari, “Oral tongue cancer in young adults less than 40 years of age: rationale for aggressive therapy,” Head and Neck, vol. 16, no. 2, pp. 107–111, 1994. View at Google Scholar
  11. R. M. Byers, “Squamous cell carcinoma of the oral tongue in patients less than thirty years of age,” American Journal of Surgery, vol. 130, no. 4, pp. 475–478, 1975. View at Google Scholar
  12. W. Zhen, L. H. Karnell, H. T. Hoffman, G. F. Funk, J. M. Buatti, and H. R. Menck, “The national cancer data base report on squamous cell carcinoma of the base of tongue,” Head and Neck, vol. 26, no. 8, pp. 660–674, 2004. View at Publisher · View at Google Scholar · View at PubMed
  13. A. Mashberg, P. Boffetta, R. Winkelman, and L. Garfinkel, “Tobacco smoking, alcohol drinking, and cancer of the oral cavity and oropharynx among U.S. Veterans,” Cancer, vol. 72, no. 4, pp. 1369–1375, 1993. View at Google Scholar
  14. P. Boffetta, A. Mashberg, R. Winkelmann, and L. Garfinkel, “Carcinogenic effect of tobacco smoking and alcohol drinking on anatomic sites of the oral cavity and oropharynx,” International Journal of Cancer, vol. 52, no. 4, pp. 530–533, 1992. View at Publisher · View at Google Scholar
  15. E. Gebhart and T. Liehr, “Patterns of genomic imbalances in human solid tumors (Review),” International Journal of Oncology, vol. 16, no. 2, pp. 383–399, 2000. View at Google Scholar
  16. P. M. Brzoska, N. A. Levin, K. K. Fu et al., “Frequent novel DNA copy number increase in squamous cell head and neck tumors,” Cancer Research, vol. 55, no. 14, pp. 3055–3059, 1995. View at Google Scholar
  17. N. A. Bergamo, S. R. Rogatto, R. C. Poli-Frederico et al., “Comparative genomic hybridization analysis detects frequent over-representation of DNA sequences at 3q, 7p, and 8q in head and neck carcinomas,” Cancer Genetics and Cytogenetics, vol. 119, no. 1, pp. 48–55, 2000. View at Publisher · View at Google Scholar
  18. B. Singh, S. K. Gogineni, P. G. Sacks et al., “Molecular cytogenetic characterization of head and neck squamous cell carcinoma and refinement of 3q amplification,” Cancer Research, vol. 61, no. 11, pp. 4506–4513, 2001. View at Google Scholar
  19. M. R. Speicher, C. Howe, P. Crotty, S. du Manoir, J. Costa, and D. C. Ward, “Comparative genomic hybridization detects novel deletions and amplifications in head and neck squamous cell carcinomas,” Cancer Research, vol. 55, no. 5, pp. 1010–1013, 1995. View at Google Scholar
  20. U. Bockmuhl, G. Wolf, S. Schmidt et al., “Genomic alterations associated with malignancy in head and neck cancer,” Head and Neck, vol. 20, no. 2, pp. 145–151, 1998. View at Publisher · View at Google Scholar
  21. R. G. Weber, M. Scheer, I. A. Born et al., “Recurrent chromosomal imbalances detected in biopsy material from oral premalignant and malignant lesions by combined tissue microdissection, universal DNA amplification, and comparative genomic hybridization,” American Journal of Pathology, vol. 153, no. 1, pp. 295–303, 1998. View at Google Scholar
  22. B. Singh, A. Stoffel, S. Gogineni et al., “Amplification of the 3q26.3 locus is associated with progression to invasive cancer and is a negative prognostic factor in head and neck squamous cell carcinomas,” American Journal of Pathology, vol. 161, no. 2, pp. 365–371, 2002. View at Google Scholar
  23. R. Redon, D. Muller, K. Caulee, K. Wanherdrick, J. Abecassis, and S. du Manoir, “A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains,” Cancer Research, vol. 61, no. 10, pp. 4122–4129, 2001. View at Google Scholar
  24. A.-E. Al Moustafa, M. A. Alaoui-Jamali, G. Batist et al., “Identification of genes associated with head and neck carcinogenesis by cDNA microarray comparison between matched primary normal epithelial and squamous carcinoma cells,” Oncogene, vol. 21, no. 17, pp. 2634–2640, 2002. View at Publisher · View at Google Scholar · View at PubMed
  25. S. B. Pattle and P. J. Farrell, “The role of Epstein-Barr virus in cancer,” Expert Opinion on Biological Therapy, vol. 6, no. 11, pp. 1193–1205, 2006. View at Publisher · View at Google Scholar · View at PubMed
  26. L. S. Young and P. G. Murray, “Epstein-Barr virus and oncogenesis: from latent genes to tumours,” Oncogene, vol. 22, no. 33, pp. 5108–5121, 2003. View at Publisher · View at Google Scholar · View at PubMed
  27. D. Liebowitz, “Nasopharyngeal carcinoma: the Epstein-Barr virus association,” Seminars in Oncology, vol. 21, no. 3, pp. 376–381, 1994. View at Google Scholar
  28. C. M. Borza and L. M. Hutt-Fletcher, “Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus,” Nature Medicine, vol. 8, no. 6, pp. 594–599, 2002. View at Publisher · View at Google Scholar · View at PubMed
  29. G. Niedobitek and L. S. Young, “Epstein-Barr virus persistence and virus-associated tumours,” The Lancet, vol. 343, no. 8893, pp. 333–335, 1994. View at Google Scholar
  30. R. Pathmanathan, U. Prasad, R. Sadler, K. Flynn, and N. Raab-Traub, “Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma,” The New England Journal of Medicine, vol. 333, no. 11, pp. 693–698, 1995. View at Publisher · View at Google Scholar
  31. P. Frangou, M. Buettner, and G. Niedobitek, “Epstein-Barr virus (EBV) infection in epithelial cells in vivo: rare detection of EBV replication in tongue mucosa but not in salivary glands,” Journal of Infectious Diseases, vol. 191, no. 2, pp. 238–242, 2005. View at Publisher · View at Google Scholar · View at PubMed
  32. R. Herrero, X. Castellsagué, M. Pawlita et al., “Human papillomavirus and oral cancer: the international agency for research on cancer multicenter study,” Journal of the National Cancer Institute, vol. 95, no. 23, pp. 1772–1783, 2003. View at Google Scholar
  33. J. Mork, A. K. Lie, E. Glattre et al., “Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck,” The New England Journal of Medicine, vol. 344, no. 15, pp. 1125–1131, 2001. View at Publisher · View at Google Scholar
  34. M. L. Gillison and K. V. Shah, “Human papillomavirus-associated head and neck squamous cell carcinoma: mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers,” Current Opinion in Oncology, vol. 13, no. 3, pp. 183–188, 2001. View at Publisher · View at Google Scholar
  35. P. B. Sugerman and E. J. Shillitoe, “The high risk human papillomaviruses and oral cancer: evidence for and against a causal relationship,” Oral Diseases, vol. 3, no. 3, pp. 130–147, 1997. View at Google Scholar
  36. W. J. Koskinen, R. W. Chen, I. Leivo et al., “Prevalence and physical status of human papillomavirus in squamous cell carcinomas of the head and neck,” International Journal of Cancer, vol. 107, no. 3, pp. 401–406, 2003. View at Publisher · View at Google Scholar · View at PubMed
  37. S. Kantola, M. Parikka, K. Jokinen et al., “Prognostic factors in tongue cancer—relative importance of demographic, clinical and histopathological factors,” British Journal of Cancer, vol. 83, no. 5, pp. 614–619, 2000. View at Google Scholar
  38. L. Dahlgren, H. Dahlstrand, D. Lindquist et al., “Human papillomavirus is more common in base of tongue than in mobile tongue cancer and is a favorable prognostic factor in base of tongue cancer patients,” International Journal of Cancer, vol. 112, no. 6, pp. 1015–1019, 2004. View at Publisher · View at Google Scholar · View at PubMed
  39. X.-H. Liang, J. Lewis, R. Foote, D. Smith, and D. Kademani, “Prevalence and significance of human papillomavirus in oral tongue cancer: the Mayo Clinic experience,” Journal of Oral and Maxillofacial Surgery, vol. 66, no. 9, pp. 1875–1880, 2008. View at Publisher · View at Google Scholar · View at PubMed
  40. D. M. Brizel, G. S. Sibley, L. R. Prosnitz, R. L. Scher, and M. W. Dewhirst, “Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck,” International Journal of Radiation Oncology Biology Physics, vol. 38, no. 2, pp. 285–289, 1997. View at Publisher · View at Google Scholar
  41. R. A. Jonathan, K. I. E. M. Wijffels, W. Peeters et al., “The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON,” Radiotherapy and Oncology, vol. 79, no. 3, pp. 288–297, 2006. View at Publisher · View at Google Scholar · View at PubMed
  42. R. E. Durand, “The influence of microenvironmental factors during cancer therapy,” In Vivo, vol. 8, no. 5, pp. 691–702, 1994. View at Google Scholar
  43. P. L. Olive and R. E. Durand, “Drug and radiation resistance in spheroids: cell contact and kinetics,” Cancer and Metastasis Reviews, vol. 13, no. 2, pp. 121–138, 1994. View at Publisher · View at Google Scholar
  44. B. A. Teicher, “Hypoxia and drug resistance,” Cancer and Metastasis Reviews, vol. 13, no. 2, pp. 139–168, 1994. View at Publisher · View at Google Scholar
  45. H. L. Janssen, K. M. Haustermans, A. J. Balm, and A. C. Begg, “Hypoxia in head and neck cancer: how much, how important?” Head and Neck, vol. 27, no. 7, pp. 622–638, 2005. View at Publisher · View at Google Scholar · View at PubMed
  46. G. U. Dachs and D. J. Chaplin, “Microenvironmental control of gene expression: implications for tumor angiogenesis, progression, and metastasis,” Seminars in Radiation Oncology, vol. 8, no. 3, pp. 208–216, 1998. View at Publisher · View at Google Scholar
  47. G. U. Dachs and G. M. Tozer, “Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation,” European Journal of Cancer, vol. 36, no. 13, pp. 1649–1660, 2000. View at Publisher · View at Google Scholar
  48. K. De Jaeger, M.-C. Kavanagh, and R. P. Hill, “Relationship of hypoxia to metastatic ability in rodent tumours,” British Journal of Cancer, vol. 84, no. 9, pp. 1280–1285, 2001. View at Publisher · View at Google Scholar · View at PubMed
  49. N. J. P. Beasley, C. C. Wykoff, P. H. Watson et al., “Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density,” Cancer Research, vol. 61, no. 13, pp. 5262–5267, 2001. View at Google Scholar
  50. E. P. Hui, A. T. C. Chan, F. Pezzella et al., “Coexpression of hypoxia-inducible factors 1α and 2α, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival,” Clinical Cancer Research, vol. 8, no. 8, pp. 2595–2604, 2002. View at Google Scholar
  51. J.-L. Roh, K.-J. Cho, G. Y. Kwon et al., “The prognostic value of hypoxia markers in T2-staged oral tongue cancer,” Oral Oncology, vol. 45, no. 1, pp. 63–68, 2009. View at Publisher · View at Google Scholar · View at PubMed
  52. A. S. Kennedy, J. A. Raleigh, G. M. Perez et al., “Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays,” International Journal of Radiation Oncology Biology Physics, vol. 37, no. 4, pp. 897–905, 1997. View at Publisher · View at Google Scholar
  53. M. A. Varia, D. P. Calkins-Adams, L. H. Rinker et al., “Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma,” Gynecologic Oncology, vol. 71, no. 2, pp. 270–277, 1998. View at Publisher · View at Google Scholar · View at PubMed
  54. K. I. Wijffels, J. H. Kaanders, P. F. Rijken et al., “Vascular architecture and hypoxic profiles in human head and neck squamous cell carcinomas,” British Journal of Cancer, vol. 83, no. 5, pp. 674–683, 2000. View at Google Scholar
  55. J. H. Kaanders, K. I. Wijffels, H. A. M. Marres et al., “Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer,” Cancer Research, vol. 62, no. 23, pp. 7066–7074, 2002. View at Google Scholar
  56. T. Veikkola, M. Karkkainen, L. Claesson-Welsh, and K. Alitalo, “Regulation of angiogenesis via vascular endothelial growth factor receptors,” Cancer Research, vol. 60, no. 2, pp. 203–212, 2000. View at Google Scholar
  57. N. Ferrara and T. Davis-Smyth, “The biology of vascular endothelial growth factor,” Endocrine Reviews, vol. 18, no. 1, pp. 4–25, 1997. View at Publisher · View at Google Scholar
  58. E. Kukk, A. Lymboussaki, S. Taira et al., “VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development,” Development, vol. 122, no. 12, pp. 3829–3837, 1996. View at Google Scholar
  59. R. Roskoski Jr., “Vascular endothelial growth factor (VEGF) signaling in tumor progression,” Critical Reviews in Oncology/Hematology, vol. 62, no. 3, pp. 179–213, 2007. View at Publisher · View at Google Scholar · View at PubMed
  60. T. Cohen, H. Gitay-Goren, R. Sharon et al., “VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells,” The Journal of Biological Chemistry, vol. 270, no. 19, pp. 11322–11326, 1995. View at Publisher · View at Google Scholar
  61. P. Salven, A. Lymboussaki, P. Heikkila et al., “Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors,” American Journal of Pathology, vol. 153, no. 1, pp. 103–108, 1998. View at Google Scholar
  62. M. Jeltsch, A. Kaipainen, V. Joukov et al., “Hyperplasia of lymphatic vessels in VEGF-C transgenic mice,” Science, vol. 276, no. 5317, pp. 1423–1425, 1997. View at Publisher · View at Google Scholar
  63. S.-J. Oh, M. M. Jeltsch, R. Birkenhager et al., “VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane,” Developmental Biology, vol. 188, no. 1, pp. 96–109, 1997. View at Publisher · View at Google Scholar · View at PubMed
  64. A. Kaipainen, J. Korhonen, T. Mustonen et al., “Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 8, pp. 3566–3570, 1995. View at Google Scholar
  65. E. Kukk, A. Lymboussaki, S. Taira et al., “VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development,” Development, vol. 122, no. 12, pp. 3829–3837, 1996. View at Google Scholar
  66. J. Benefield, G. J. Petruzzelli, S. Fowler, A. Taitz, J. Kalkanis, and M. R. I. Young, “Regulation of the steps of angiogenesis by human head and neck squamous cell carcinomas,” Invasion and Metastasis, vol. 16, no. 6, pp. 291–301, 1996. View at Google Scholar
  67. P. O-Charoenrat, P. Rhys-Evans, and S. A. Eccles, “Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis,” Cancer, vol. 92, no. 3, pp. 556–568, 2001. View at Publisher · View at Google Scholar
  68. B. S. Siriwardena, Y. Kudo, I. Ogawa, M. N. Udagama, W. M. Tilakaratne, and T. Takata, “VEGF-C is associated with lymphatic status and invasion in oral cancer,” Journal of Clinical Pathology, vol. 61, no. 1, pp. 103–108, 2008. View at Publisher · View at Google Scholar · View at PubMed
  69. K. Kishimoto, A. Sasaki, Y. Yoshihama, H. Mese, G. Tsukamoto, and T. Matsumura, “Expression of vascular endothelial growth factor-C predicts regional lymph node metastasis in early oral squamous cell carcinoma,” Oral Oncology, vol. 39, no. 4, pp. 391–396, 2003. View at Publisher · View at Google Scholar
  70. S. H. Kim, N. H. Cho, K. Kim et al., “Correlations of oral tongue cancer invasion with matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF) expression,” Journal of Surgical Oncology, vol. 93, no. 4, pp. 330–337, 2006. View at Google Scholar
  71. S. E. S. Faustino, D. T. Oliveira, S. Nonogaki, G. Landman, A. L. Carvalho, and L. P. Kowalski, “Expression of vascular endothelial growth factor-C does not predict occult lymph-node metastasis in early oral squamous cell carcinoma,” International Journal of Oral and Maxillofacial Surgery, vol. 37, no. 4, pp. 372–378, 2008. View at Publisher · View at Google Scholar · View at PubMed
  72. J. H. Cho, H.-S. Kim, C.-S. Park et al., “Maspin expression in early oral tongue cancer and its relation to expression of mutant-type p53 and vascular endothelial growth factor (VEGF),” Oral Oncology, vol. 43, no. 3, pp. 272–277, 2007. View at Publisher · View at Google Scholar · View at PubMed
  73. S. Sheng, “The promise and challenge toward the clinical application of maspin in cancer,” Frontiers in Bioscience, vol. 9, pp. 2733–2745, 2004. View at Google Scholar
  74. M. Zhang, O. Volpert, Y. H. Shi, and N. Bouck, “Maspin is an angiogenesis inhibitor,” Nature Medicine, vol. 6, no. 2, pp. 196–199, 2000. View at Publisher · View at Google Scholar · View at PubMed
  75. A. Le Querrec, D. Duval, and G. Tobelem, “Tumour angiogenesis,” Bailliere's Clinical Haematology, vol. 6, no. 3, pp. 711–730, 1993. View at Publisher · View at Google Scholar
  76. S. M. Ellerbroek, J. M. Halbleib, M. Benavidez et al., “Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association,” Cancer Research, vol. 61, no. 5, pp. 1855–1861, 2001. View at Google Scholar
  77. R. Agarwal, T. D'Souza, and P. J. Morin, “Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity,” Cancer Research, vol. 65, no. 16, pp. 7378–7385, 2005. View at Publisher · View at Google Scholar · View at PubMed
  78. Y. Hayashida, K. Honda, M. Idogawa et al., “E-cadherin regulates the association between β-catenin and actinin-4,” Cancer Research, vol. 65, no. 19, pp. 8836–8845, 2005. View at Publisher · View at Google Scholar · View at PubMed
  79. H. Nei, T. Saito, H. Tobioka, E. Itoh, M. Mori, and R. Kudo, “Expression of component desmosomal proteins in uterine endometrial carcinoma and their relation to cellular differentiation,” Cancer, vol. 78, no. 3, pp. 461–470, 1996. View at Publisher · View at Google Scholar
  80. A. Bazarbachi, R. Abou Merhi, A. Gessain et al., “Human T-cell lymphotropic virus type I-infected cells extravasate through the endothelial barrier by a local angiogenesis-like mechanism,” Cancer Research, vol. 64, no. 6, pp. 2039–2046, 2004. View at Publisher · View at Google Scholar
  81. L. Gonzalez-Mariscal, A. Betanzos, P. Nava, and B. E. Jaramillo, “Tight junction proteins,” Progress in Biophysics and Molecular Biology, vol. 81, no. 1, pp. 1–44, 2003. View at Publisher · View at Google Scholar
  82. L. L. Mitic and J. M. Anderson, “Molecular architecture of tight junctions,” Annual Review of Physiology, vol. 60, pp. 121–142, 1998. View at Publisher · View at Google Scholar · View at PubMed
  83. J. M. Mullin, “Potential interplay between luminal growth factors and increased tight junction permeability in epithelial carcinogenesis,” Journal of Experimental Zoology, vol. 279, no. 5, pp. 484–489, 1997. View at Publisher · View at Google Scholar
  84. Y. Soini, “Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of tumours,” Histopathology, vol. 46, no. 5, pp. 551–560, 2005. View at Publisher · View at Google Scholar · View at PubMed
  85. N. Oku, E. Sasabe, E. Ueta, T. Yamamoto, and T. Osaki, “Tight junction protein claudin-1 enhances the invasive activity of oral squamous cell carcinoma cells by promoting cleavage of laminin-5 γ2 chain via matrix metalloproteinase (MMP)-2 and membrane-type MMP-1,” Cancer Research, vol. 66, no. 10, pp. 5251–5257, 2006. View at Publisher · View at Google Scholar · View at PubMed
  86. I. O. Bello, S.-T. Vilen, A. Niinimaa, S. Kantola, Y. Soini, and T. Salo, “Expression of claudins 1, 4, 5, and 7 and occludin, and relationship with prognosis in squamous cell carcinoma of the tongue,” Human Pathology, vol. 39, no. 8, pp. 1212–1220, 2008. View at Publisher · View at Google Scholar · View at PubMed
  87. N. C. Popescu, C. R. King, and M. H. Kraus, “Localization of the human ErbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32,” Genomics, vol. 4, no. 3, pp. 362–366, 1989. View at Google Scholar
  88. M. A. Olayioye, R. M. Neve, H. A. Lane, and N. E. Hynes, “The ErbB signaling network: receptor heterodimerization in development and cancer,” The EMBO Journal, vol. 19, no. 13, pp. 3159–3167, 2000. View at Google Scholar
  89. W. Xia, Y.-K. Lau, H.-Z. Zhang et al., “Strong correlation between c-ErbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma,” Clinical Cancer Research, vol. 3, no. 1, pp. 3–9, 1997. View at Google Scholar
  90. W. Xia, Y.-K. Lau, H.-Z. Zhang et al., “Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members,” Clinical Cancer Research, vol. 5, no. 12, pp. 4164–4174, 1999. View at Google Scholar
  91. R. Werkmeister, B. Brandt, and U. Joos, “Clinical relevance of ErbB-1 and -2 oncogenes in oral carcinomas,” Oral Oncology, vol. 36, no. 1, pp. 100–105, 2000. View at Publisher · View at Google Scholar
  92. R. Bei, G. Pompa, D. Vitolo et al., “Co-localization of multiple ErbB receptors in stratified epithelium of oral squamous cell carcinoma,” Journal of Pathology, vol. 195, no. 3, pp. 343–348, 2001. View at Publisher · View at Google Scholar · View at PubMed
  93. A. J. Khan, B. L. King, B. D. Smith et al., “Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma,” Clinical Cancer Research, vol. 8, no. 2, pp. 540–548, 2002. View at Google Scholar
  94. B. Khademi, F. M. Shirazi, M. Vasei et al., “The expression of p53, c-ErbB-1 and c-ErbB-2 molecules and their correlation with prognostic markers in patients with head and neck tumors,” Cancer Letters, vol. 184, no. 2, pp. 223–230, 2002. View at Publisher · View at Google Scholar
  95. D. Innocenzi, P. L. Alo, A. Balzani et al., “Fatty acid synthase expression in melanoma,” Journal of Cutaneous Pathology, vol. 30, no. 1, pp. 23–28, 2003. View at Publisher · View at Google Scholar
  96. T. Takahiro, K. Shinichi, and S. Toshimitsu, “Expression of fatty acid synthase as a prognostic indicator in soft tissue sarcomas,” Clinical Cancer Research, vol. 9, no. 6, pp. 2204–2212, 2003. View at Google Scholar
  97. P. L. Alo, P. Visca, M. L. Framarino et al., “Immunohistochemical study of fatty acid synthase in ovarian neoplasms,” Oncology Reports, vol. 7, no. 6, pp. 1383–1388, 2000. View at Google Scholar
  98. T. Kusakabe, A. Nashimoto, K. Honma, and T. Suzuki, “Fatty acid synthase is highly expressed in carcinoma, adenoma and in regenerative epithelium and intestinal metaplasia of the stomach,” Histopathology, vol. 40, no. 1, pp. 71–79, 2002. View at Publisher · View at Google Scholar
  99. S. D. Silva, M. Agostini, I. N. Nishimoto et al., “Expression of fatty acid synthase, ErbB2 and Ki-67 in head and neck squamous cell carcinoma. A clinicopathological study,” Oral Oncology, vol. 40, no. 7, pp. 688–696, 2004. View at Publisher · View at Google Scholar · View at PubMed
  100. M. Agostini, S. D. Silva, K. G. Zecchin et al., “Fatty acid synthase is required for the proliferation of human oral squamous carcinoma cells,” Oral Oncology, vol. 40, no. 7, pp. 728–735, 2004. View at Publisher · View at Google Scholar · View at PubMed
  101. A. Jayakumar, M.-H. Tai, W.-Y. Huang et al., “Human fatty acid synthase: properties and molecular cloning,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 19, pp. 8695–8699, 1995. View at Publisher · View at Google Scholar
  102. J. A. Menendez, R. Lupu, and R. Colomer, “Targeting fatty acid synthase: potential for therapeutic intervention in Her-2/neu-overexpressing breast cancer,” Drug News and Perspectives, vol. 18, no. 6, pp. 375–385, 2005. View at Publisher · View at Google Scholar · View at PubMed
  103. S. D. Silva, D. E. Perez, F. A. Alves et al., “ErbB2 and fatty acid synthase (FAS) expression in 102 squamous cell carcinomas of the tongue: correlation with clinical outcomes,” Oral Oncology, vol. 44, no. 5, pp. 484–490, 2008. View at Publisher · View at Google Scholar · View at PubMed
  104. S. D. Silva, D. E. Perez, I. N. Nishimoto et al., “Fatty acid synthase expression in squamous cell carcinoma of the tongue: clinicopathological findings,” Oral Diseases, vol. 14, no. 4, pp. 376–382, 2008. View at Publisher · View at Google Scholar · View at PubMed
  105. F. Angiero, R. D. Sordo, E. Dessy et al., “Comparative analysis of c-ErbB-2 (HER-2/neu) in squamous cell carcinoma of the tongue: does over-expression exist? And what is its correlation with traditional diagnostic parameters?” Journal of Oral Pathology and Medicine, vol. 37, no. 3, pp. 145–150, 2008. View at Publisher · View at Google Scholar · View at PubMed
  106. F. Chang, S. Syrjanen, and K. Syrjanen, “Implications of the p53 tumor-suppressor gene in clinical oncology,” Journal of Clinical Oncology, vol. 13, no. 4, pp. 1009–1022, 1995. View at Google Scholar
  107. S. W. Lowe, S. Bodis, A. McClatchey et al., “p53 status and the efficacy of cancer therapy in vivo,” Science, vol. 266, no. 5186, pp. 807–810, 1994. View at Google Scholar
  108. S. W. Lowe, H. E. Ruley, T. Jacks, and D. E. Housman, “p53-dependent apoptosis modulates the cytotoxicity of anticancer agents,” Cell, vol. 74, no. 6, pp. 957–967, 1993. View at Publisher · View at Google Scholar
  109. H. Suzuki, T. Takahashi, T. Kuroishi et al., “p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking,” Cancer Research, vol. 52, no. 3, pp. 734–736, 1992. View at Google Scholar
  110. X. Wang, D. C. Christiani, J. K. Wiencke et al., “Mutations in the p53 gene in lung cancer are associated with cigarette smoking and asbestos exposure,” Cancer Epidemiology Biomarkers and Prevention, vol. 4, no. 5, pp. 543–548, 1995. View at Google Scholar
  111. J. K. Field, D. A. Spandidos, A. Malliri, J. R. Gosney, M. Yiagnisis, and P. M. Stell, “Elevated P53 expression correlates with a history of heavy smoking in squamous cell carcinoma of the head and neck,” British Journal of Cancer, vol. 64, no. 3, pp. 573–577, 1991. View at Google Scholar
  112. J. B. Matthews, C. Scully, A. Jovanovic, I. Van der Waal, W. A. Yeudall, and S. S. Prime, “Relationship of tobacco/alcohol use to p53 expression in patients with lingual squamous cell carcinomas,” European Journal of Cancer Part B, vol. 29, no. 4, pp. 285–289, 1993. View at Publisher · View at Google Scholar
  113. S. Atula, K. Kurvinen, R. Grinman, and S. Syrjken, “SSCP pattern indicative for p53 mutation is related to advanced stage and high-grade of tongue cancer,” European Journal of Cancer Part B, vol. 32, no. 4, pp. 222–229, 1996. View at Publisher · View at Google Scholar
  114. Y. Sameshima, Y. Matsuno, S. Hirohashi et al., “Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma,” Oncogene, vol. 7, no. 3, pp. 451–457, 1992. View at Google Scholar
  115. J. Pohl, N. Goldfinger, A. Radler-Pohl, V. Rotter, and V. Schirrmacher, “p53 increases experimental metastatic capacity of murine carcinoma cells,” Molecular and Cellular Biology, vol. 8, no. 5, pp. 2078–2081, 1988. View at Google Scholar
  116. B. Vogelstein, “A deadly inheritance,” Nature, vol. 348, no. 6303, pp. 681–682, 1990. View at Publisher · View at Google Scholar · View at PubMed
  117. H. H. Vora, T. I. Trivedi, S. N. Shukla, N. G. Shah, J. V. Goswami, and P. M. Shah, “p53 expression in leukoplakia and carcinoma of the tongue,” International Journal of Biological Markers, vol. 21, no. 2, pp. 74–80, 2006. View at Google Scholar
  118. R. M. Nagler, H. Kerner, D. Laufer, S. Ben-Eliezer, I. Minkov, and O. Ben-Itzhak, “Squamous cell carcinoma of the tongue: the prevalence and prognostic roles of p53, Bcl-2, c-ErbB-2 and apoptotic rate as related to clinical and pathological characteristics in a retrospective study,” Cancer Letters, vol. 186, no. 2, pp. 137–150, 2002. View at Publisher · View at Google Scholar
  119. K. C. Keum, E. J. Chung, W. S. Koom et al., “Predictive value of p53 and PCNA expression for occult neck metastases in patients with clinically node-negative oral tongue cancer,” Otolaryngology: Head and Neck Surgery, vol. 135, no. 6, pp. 858–864, 2006. View at Publisher · View at Google Scholar · View at PubMed
  120. D. R. Senger, D. F. Wirth, and R. O. Hynes, “Transformed mammalian cells secrete specific proteins and phosphoproteins,” Cell, vol. 16, no. 4, pp. 885–893, 1979. View at Google Scholar
  121. L. Liaw, M. P. Skinner, E. W. Raines et al., “The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of α(v)β3 in smooth muscle cell migration to osteopontin in vitro,” Journal of Clinical Investigation, vol. 95, no. 2, pp. 713–724, 1995. View at Google Scholar
  122. P. Y. Wai and P. C. Kuo, “The role of osteopontin in tumor metastasis,” Journal of Surgical Research, vol. 121, no. 2, pp. 228–241, 2004. View at Publisher · View at Google Scholar · View at PubMed
  123. H. Singhai, D. S. Bautista, K. S. Tonkin et al., “Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival,” Clinical Cancer Research, vol. 3, no. 4, pp. 605–611, 1997. View at Google Scholar
  124. T. Ue, H. Yokozaki, Y. Kitadai et al., “Co-expression of osteopontin and CD44v9 in gastric cancer,” International Journal of Cancer, vol. 79, no. 2, pp. 127–132, 1998. View at Publisher · View at Google Scholar
  125. J.-H. Kim, S. J. Skates, T. Uede et al., “Osteopontin as a potential diagnostic biomarker for ovarian cancer,” Journal of the American Medical Association, vol. 287, no. 13, pp. 1671–1679, 2002. View at Google Scholar
  126. D. Agrawal, T. Chen, R. Irby et al., “Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling,” Journal of the National Cancer Institute, vol. 94, no. 7, pp. 513–521, 2002. View at Google Scholar
  127. A. J. Oates, R. Barraclough, and P. S. Rudland, “The role of osteopontin in tumorigenesis and metastasis,” Invasion and Metastasis, vol. 17, no. 1, pp. 1–15, 1997. View at Google Scholar
  128. G. F. Weber, “The metastasis gene osteopontin: a candidate target for cancer therapy,” Biochimica et Biophysica Acta, vol. 1552, no. 2, pp. 61–85, 2001. View at Publisher · View at Google Scholar
  129. A. B. Tuck, D. M. Arsenault, F. P. O'Malley et al., “Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells,” Oncogene, vol. 18, no. 29, pp. 4237–4246, 1999. View at Publisher · View at Google Scholar · View at PubMed
  130. H. Matsuzaki, K. Shima, T. Muramatsu et al., “Osteopontin as biomarker in early invasion by squamous cell carcinoma in tongue,” Journal of Oral Pathology and Medicine, vol. 36, no. 1, pp. 30–34, 2007. View at Publisher · View at Google Scholar · View at PubMed
  131. C.-Y. Chien, C.-Y. Su, H.-C. Chuang et al., “Clinical significance of osteopontin expression in T1 and T2 tongue cancers,” Head and Neck, vol. 30, no. 6, pp. 776–781, 2008. View at Publisher · View at Google Scholar · View at PubMed
  132. G. Ambrosini, C. Adida, and D. C. Altieri, “A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma,” Nature Medicine, vol. 3, no. 8, pp. 917–921, 1997. View at Publisher · View at Google Scholar
  133. Q. L. Deveraux and J. C. Reed, “IAP family proteins—suppressors of apoptosis,” Genes and Development, vol. 13, no. 3, pp. 239–252, 1999. View at Google Scholar
  134. N. A. Thornberry, “Caspases: a decade of death research,” Cell Death and Differentiation, vol. 6, no. 11, pp. 1023–1027, 1999. View at Google Scholar
  135. T. Dohi, K. Okada, F. Xia et al., “An IAP-IAP complex inhibits apoptosis,” The Journal of Biological Chemistry, vol. 279, no. 33, pp. 34087–34090, 2004. View at Publisher · View at Google Scholar · View at PubMed
  136. L. Lo Muzio, A. Farina, C. Rubini et al., “Survivin as prognostic factor in squamous cell carcinoma of the oral cavity,” Cancer Letters, vol. 225, no. 1, pp. 27–33, 2005. View at Publisher · View at Google Scholar · View at PubMed
  137. C.-Y. Lin, H.-C. Hung, R.-C. Kuo, C.-P. Chiang, and M. Y.-P. Kuo, “Survivin expression predicts poorer prognosis in patients with areca quid chewing-related oral squamous cell carcinoma in Taiwan,” Oral Oncology, vol. 41, no. 6, pp. 645–654, 2005. View at Publisher · View at Google Scholar · View at PubMed
  138. K. Freier, S. Pungs, C. Sticht et al., “High survivin expression is associated with favorable outcome in advanced primary oral squamous cell carcinoma after radiation therapy,” International Journal of Cancer, vol. 120, no. 4, pp. 942–946, 2007. View at Publisher · View at Google Scholar · View at PubMed
  139. G. Carpenter and S. Cohen, “Epidermal growth factor,” The Journal of Biological Chemistry, vol. 265, no. 14, pp. 7709–7712, 1990. View at Google Scholar
  140. D. Hardisson, “Molecular pathogenesis of head and neck squamous cell carcinoma,” European Archives of Oto-Rhino-Laryngology, vol. 260, no. 9, pp. 502–508, 2003. View at Publisher · View at Google Scholar · View at PubMed
  141. S. Kalyankrishna and J. R. Grandis, “Epidermal growth factor receptor biology in head and neck cancer,” Journal of Clinical Oncology, vol. 24, no. 17, pp. 2666–2672, 2006. View at Publisher · View at Google Scholar · View at PubMed
  142. J. R. Grandis and D. J. Tweardy, “Elevated levels of transforming growth factor and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer,” Cancer Research, vol. 53, no. 15, pp. 3579–3584, 1993. View at Google Scholar
  143. X. Pivot, N. Magné, E. Guardiola et al., “Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer,” Oral Oncology, vol. 41, no. 3, pp. 320–327, 2005. View at Publisher · View at Google Scholar · View at PubMed
  144. R. Hitt, E. Ciruelos, M. L. Amador et al., “Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy,” European Journal of Cancer, vol. 41, no. 3, pp. 453–460, 2005. View at Publisher · View at Google Scholar · View at PubMed
  145. K. K. Ang, B. A. Berkey, X. Tu et al., “Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma,” Cancer Research, vol. 62, no. 24, pp. 7350–7356, 2002. View at Google Scholar
  146. K. Liang, K. K. Ang, L. Milas, N. Hunter, and Z. Fan, “The epidermal growth factor receptor mediates radioresistance,” International Journal of Radiation Oncology Biology Physics, vol. 57, no. 1, pp. 246–254, 2003. View at Publisher · View at Google Scholar
  147. K. Katoh, Y. Nakanishi, S. Akimoto et al., “Correlation between laminin-5 γ2 chain expression and epidermal growth factor receptor expression and its clinicopathological significance in squamous cell carcinoma of the tongue,” Oncology, vol. 62, no. 4, pp. 318–326, 2002. View at Publisher · View at Google Scholar
  148. J. Santini, J.-L. Formento, M. Francoual et al., “Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas,” Head and Neck, vol. 13, no. 2, pp. 132–139, 1991. View at Google Scholar
  149. J. R. Grandis, M. F. Melhem, E. L. Barnes, and D. J. Tweardy, “Quantitative immunohistochemical analysis of transforming growth factor-α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck,” Cancer, vol. 78, no. 6, pp. 1284–1292, 1996. View at Publisher · View at Google Scholar
  150. D. A. Eberhard, B. E. Johnson, L. C. Amler et al., “Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib,” Journal of Clinical Oncology, vol. 23, no. 25, pp. 5900–5909, 2005. View at Publisher · View at Google Scholar · View at PubMed
  151. L. J. Wirth, R. I. Haddad, N. I. Lindeman et al., “Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck,” Journal of Clinical Oncology, vol. 23, no. 28, pp. 6976–6981, 2005. View at Publisher · View at Google Scholar · View at PubMed
  152. E. E. W. Cohen, F. Rosen, W. M. Stadler et al., “Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck,” Journal of Clinical Oncology, vol. 21, no. 10, pp. 1980–1987, 2003. View at Publisher · View at Google Scholar · View at PubMed
  153. J. W. Lee, Y. H. Soung, S. Y. Kim et al., “Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck,” Clinical Cancer Research, vol. 11, no. 8, pp. 2879–2882, 2005. View at Publisher · View at Google Scholar · View at PubMed
  154. A. L. Mahmoud, A. Sheikh, G. M. Gunduz et al., “Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma,” Cancer Science, vol. 98, no. 8, pp. 1589–1594, 2008. View at Publisher · View at Google Scholar · View at PubMed
  155. Y. Lemos-González, M. Páez de la Cadena, F. J. Rodríguez-Berrocal, A. M. Rodríguez-Piñeiro, E. Pallas, and D. Valverde, “Absence of activating mutations in the EGFR kinase domain in spanish head and neck cancer patients,” Tumor Biology, vol. 28, no. 5, pp. 273–279, 2007. View at Publisher · View at Google Scholar · View at PubMed
  156. J. Loeffler-Ragg, M. Witsch-Baumgartner, A. Tzankov et al., “Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma,” European Journal of Cancer, vol. 42, no. 1, pp. 109–111, 2006. View at Publisher · View at Google Scholar · View at PubMed
  157. D. Ulanovski, Y. Stern, P. Roizman, T. Shpitzer, A. Popovtzer, and R. Feinmesser, “Expression of EGFR and Cerb-B2 as prognostic factors in cancer of the tongue,” Oral Oncology, vol. 40, no. 5, pp. 532–537, 2004. View at Publisher · View at Google Scholar · View at PubMed